May 4 (Reuters) – Takeda Pharmaceutical said on Monday its experimental drug for primary immunodeficiency disease, a rare condition that weakens the immune system, has met the main goal of a mid- to late-stage trial.
The Japan-based drugmaker said the drug TAK-881 delivered comparable protective antibody levels in the blood as its approved treatment HyQvia, while requiring only half the infusion volume and less time to administer.
Both medicines boost immunity by delivering antibodies taken from human plasma, the company said.
Takeda was testing TAK-881 in adults and children aged two years and older, who were already receiving immunoglobulin therapy, and said it had a similar safety profile to HyQvia, with no new safety concerns seen.
The results could help ease the treatment burden for patients who often need frequent and lengthy infusions, the company said, adding that it plans to seek approvals for TAK-881 in the U.S., the European Union and Japan in fiscal year 2026.
(Reporting by Sahil Pandey in Bengaluru; Editing by Shilpi Majumdar)
